IL7 and prostate carcinoma: Collectively, our in vivo results elucidated that NKG2D-based CAR T cells could effectively kill prostate cancer cells, and co-expression of IL-7 could enhance the antitumor function of NKG2D-CAR T cells against prostate cancer.